SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Subscribe To Our Newsletter & Stay Updated
